Search academic texts

Information × Registration Number 0221U104832, 0119U000578 , R & D reports Title Optimize the comprehensive treatment of children with central nervous system embryonic tumors, tumors of the family of Yuinga sarcoma / primitive neuroectodermal tumors and high-risk neuroblastomas popup.stage_title Head Klymniuk Hryhorii I, Registration Date 25-04-2021 Organization National Cancer Institute popup.description2  Object of study: results of treatment of 262 children with embryonic tumors of the CNS, tumors of the Ewing's sarcoma / PNEP family (SUE / PNEP) and neuroblastomas of high-risk groups. The overall survival of transplanted patients is 42% (NB) and 32.5% (SU / PNEP) of patients, while non-transplanted patients are 10% and 27.5% of patients, respectively. The optimal modes of conditioning of VDHT with autoTSKPK in the treatment of tumors of the family SU / PNEP and NB high-risk group in children are BuMel and MES. The introduction of the technique of double (tandem) VDHT with autoTSKPK statistically significantly increased the recurrence-free survival of children with high-risk NB by 8.3%. The overall survival of patients who underwent only one element of VDHT with autologous TSKPK is 51.8%, recurrence-free - 38.5%. The overall survival of patients who underwent double (tandem) VDHT with autologous TSKPK is 63.2%, relapse-free - 46.8%. The difference is statistically significant, p = 0.02. The introduction of the technique of double (tandem) VDHT with autoTSKPK statistically significantly increased the survival of children with embryonic tumors of the CNS by 37.2%. The overall survival of transplanted patients was 76.9%. The introduction of the developed method of chemotherapy of the 2nd line gave the following results: Group I (47 patients, scheme - irinotecan, temozolomide) - recurrence-free survival was 27.0% (95%, CI: 12.1-41.8%), median 6.9 months; overall 1-year survival was 88.9% (95% CI: 79.7-98.1%); Group II (9 patients, regimen - irinotecan, temozolomide, bevacizumab) overall 1-year survival 66.6% (95%, CI: 59.1-71.8%). The use of extracorporeal irradiated autobone allowed to expand the possibility of performing organ-saving operations. This method made it possible to install an oncoendoprosthesis with a large length of resection without violating the ablation. At some localizations of paraosal sarcomas this method allowed to carry out organ-preserving surgi Product Description popup.authors Velymchanytsya Mykhaylo V Prikhodko Iryna О Shaida Elen V popup.nrat_date 2021-04-25 Close